Rituximab
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.
🧴 Clinical Application
Administer intravenously as a slow infusion only. NEVER administer as an IV push or bolus. MANDATORY PREMEDICATIONS 30 to 60 minutes prior to EVERY infusion: 1) Paracetamol/Acetaminophen (650-1000 mg oral); 2) Antihistamine (Diphenhydramine 50 mg IV/oral); 3) Corticosteroid (Methylprednisolone 100 mg IV for non-lymphoma/RA indications). Initiate infusion at 50 mg/hr; titrate upward by 50 mg/hr every 30 minutes to a maximum of 400 mg/hr as tolerated.
⚠️ Side Effects
Common: Infusion reactions (fever, chills, rigors, flushing, urticaria, hypotension occurring in >50% during first infusion), transient lymphopenia, fatigue, nausea, headache. Rare/Severe: Fatal infusion reactions, severe mucocutaneous reactions (Stevens-Johnson syndrome), Hepatitis B Virus reactivation, and Progressive Multifocal Leukoencephalopathy (PML).
🛡️ Safety Warnings
Black Box Warning: Fatal infusion-related reactions (typically within 30-120 minutes of first infusion); slow titration and premedication are mandatory. Black Box Warning: Severe mucocutaneous reactions. Black Box Warning: Hepatitis B virus (HBV) reactivation leading to fulminant hepatitis and death; screen all patients for HBsAg and anti-HBc prior to initiation. Black Box Warning: Progressive Multifocal Leukoencephalopathy (PML caused by JC virus).
Jan Aushadhi Products containing Rituximab
Found 2 generic formulation(s) containing this active ingredient.
Rituximab 100mg/10ml Injection
Rituximab Injection (100mg/10ml, 500mg/50ml) is a genetically engineered chimeric murine/human IgG1-kappa monoclonal antibody on the WHO Model List of Essential Medicines targeting the transmembrane CD20 antigen expressed on pre-B and mature B lymphocytes. Binding of rituximab to CD20 triggers complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and direct structural apoptosis, rapidly clearing normal and malignant B-cells from circulation. Indicated for Non-Hodgkin Lymphoma (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis refractory to anti-TNF agents, Granulomatosis with Polyangiitis (Wegener's), and Pemphigus Vulgaris.
Rituximab 500mg/50ml Injection
Rituximab Injection (100mg/10ml, 500mg/50ml) is a genetically engineered chimeric murine/human IgG1-kappa monoclonal antibody on the WHO Model List of Essential Medicines targeting the transmembrane CD20 antigen expressed on pre-B and mature B lymphocytes. Binding of rituximab to CD20 triggers complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and direct structural apoptosis, rapidly clearing normal and malignant B-cells from circulation. Indicated for Non-Hodgkin Lymphoma (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis refractory to anti-TNF agents, Granulomatosis with Polyangiitis (Wegener's), and Pemphigus Vulgaris.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Rituximab.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Rituximab 100mg/10ml Injection | 10ml vial | ₹3750.00 | RITUXEM, RITUXIREL, REDITUX, MABTAS, ENFIERA | ₹13141.69 | 71% Save |
| Rituximab 500mg/50ml Injection | 50ml vial | ₹10968.75 | RITUXIREL, ENFIERA | ₹14851.19 | 26% Save |
Frequently Asked Questions (FAQ)
Get answers to common queries about Rituximab generics.